You are viewing an old version of this page. View the current version.

Compare with Current View Page History

« Previous Version 4 Next »

The IFNG Response test toward M. Tuberculosis is modeled in the LB domain, in the TB-TAUG as the following:

ELISA:

ELISPOT:

There are several issues with this modeling:

  1. Where do you show that this challenge assay is done against TB antigens?
  2. CP domain has developed a new standard variable called Test Condition Agent/CNDAGT, which is used to map stimulating agents, like the values in ASSYAG, so this CP new variable can be added to LB?
  3. Lastly, this is a immunological test, should this be represented in LB?
    1. Use NHOID to show the name of the bug (in this case M. tuberculosis.) to which the INFg response is evoked? If we model this test in IS, what about its value in LB. Or can we draw the line where if we are running a routine lab test looking for IFNg level it goes to LB vs IFNg response test toward a specific, known bug then it goes to IS? Addtionally we may want to use NHOID to show the bug in either LB or IS. I remember this being discussed by Jon/Bess when they worked on the TB TAUG.

If we were to model this in IS:

$titleHtml

xx.xpt

Row

STUDYID

DOMAIN

USUBJID

ISSEQ

ISGRPID

NHOID

ISTESTCD

ISTEST

ISCNDAGT

ISTSTDTLISCATISSCAT

ISORRES

ISORRESU

ISSTRESC

ISSTRESN

ISSTRESU

ISSPEC

ISMETHOD

VISITNUMVISIT

ISDTC

1

ABC

IS

ABC-01-201

1

1

Mycobacterium tuberculosis

IFNG

Interferon Gamma

Influenza A Virus
Hemagglutination Inhibition TiterVACCINE-RELATED IMMUNOGENICITYHUMORAL IMMUNITY

40

titer

40

40

titer

SERUM

HEMAGGLUTINATION INHIBITION ASSAY

1VISIT 1

2017-05-27

2

ABC

IS

TB1230-011

2

1

Mycobacterium tuberculosisIFNG

Interferon Gamma

Influenza B Virus

Hemagglutination Inhibition TiterVACCINE-RELATED IMMUNOGENICITYHUMORAL IMMUNITY

80

titer

80

80

titer

SERUM

HEMAGGLUTINATION INHIBITION ASSAY

1VISIT 1

2017-07-27

3ABCIS










































$warningHtml

  • No labels